A new vaccine for tuberculosis: The challenges of development and deployment

Journal of Bioethical Inquiry

Volumn 6, Issue 2, 2009, Pages 219-228

  Fletcher, Helen A ^a   Hawkridge, Tony ^b   McShane, Helen ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b Aeras Global TB Vaccine Foundation South Africa   (South Africa)

Author keywords

BCG vaccine; Biological markers; Tuberculosis; Tuberculosis vaccines

Indexed keywords

EID: 70349802371     PISSN: 11767529     EISSN: 18724353     Source Type: Journal    
DOI: 10.1007/s11673-009-9153-6     Document Type: Article

References (31)

1. Alcorn, K. 2008. TB vaccine reduces new cases by almost 40% in people with HIV. Aidsmap News. 20 October. http://www.aidsmap.com/en/news/0C1FB0AF-9BC6-4A7A-8D47-7D8ABBD3C8E9.asp. Accessed 4 April 2009.
2. Baldwin, S.L., C. D'Souza, A.D. Roberts, B.P. Kelly, A.A. Frank, M.A. Lui, J.B. Ulmer, K. Huygen, D.M. McMurray, and I.M. Orme. 1998. Evaluation of new vaccines in the mouse and guinea pig model of tuberculosis. Infection and Immunity 66(6): 2951-2959.
3. Brennan, M.J., U. Fruth, J. Milstien, R. Tiernan, S. de Andrade Nishioka, and L. Chocarro. 2007. Development of new tuberculosis vaccines: A global perspective on regulatory issues. PLoS Medicine 4(8): e252. doi:10.1371/journal.pmed.0040252.
4. Buchbinder, S.P., D.V. Mehrotra, A. Duerr, D.W. Fitzgerald, R. Mogg, D. Li, P.B. Gilbert, J.R. Lama, M. Marmor, C. Del Rio, M.J. McElrath, D.R. Casimiro, K.M. Gottesdiener, J.A. Chodakewitz, L. Corey, and M.N. Robertson. 2008. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): A double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372(9653): 1881-1893. doi:10.1016/S0140-6736(08)61591-3.
5. Centers for Disease Control, Prevention (CDC). 2006. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs-worldwide, 2000-2004. MMWR. Morbidity and Mortality Weekly Report 55(11): 301-305.
6. Colditz, G.A., T.F. Brewer, C.S. Berkey, M.E. Wilson, E. Burdick, H.V. Fineberg, and F. Mosteller. 1994. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. Journal of the American Medical Association 271(9): 698-702. doi:10.1001/jama.271.9.698.
7. Connelly, D., Y. Veriava, S. Roberts, J. Tsotetsi, A. Jordan, E. DeSilva, S. Rosen, and M.B. DeSilva. 2007. Prevalence of HIV infection and median CD4 counts among health care workers in South Africa. South African Medical Journal 97(2): 115-120.
8. Corbett, E.L., C.J. Watt, N. Walker, D. Maher, B.G. Williams, M.C. Raviglione, and C. Dye. 2003. The growing burden of tuberculosis: Global trends and interactions with the HIV epidemic. Archives of Internal Medicine 163(9): 1009-1021. doi:10.1001/archinte.163.9.1009.
9. Gandhi, N.R., A. Moll, A.W. Sturm, R. Pawinski, T. Govender, U. Lalloo, K. Zeller, J. Andrews, and G. Friedland. 2006. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 368(9547): 1575-1580. doi:10.1016/S0140-6736(06)69573-1.
10. Garattini, S., and V. Bertele. 2007. How can we regulate medicines better? BMJ (Clinical Research Ed.) 335(7624): 803-805. doi:10.1136/bmj.39281.615706.94.
11. Hanekom, W.A., H.M. Dockrell, T.H. Ottenhoff, T.M. Doherty, H. Fletcher, H. McShane, F.F. Weichold, D.F. Hoft, S.K. Parida, and U.J. Fruth. 2008. Immunological outcomes of new tuberculosis vaccine trials: WHO panel recommendations. PLoS Medicine 5(7): e145. doi:10.1371/journal.pmed.0050145.
12. Huygen, K., J. Content, O. Denis, D.L. Montgomery, A.M. Yawman, R.R. Deck, C.M. DeWitt, I.M. Orme, S. Baldwin, C. D'Souza, A. Drowart, E. Lozes, P. Vandenbussche, J.P. van Vooren, M.A. Liu, and J.B. Ulmer. 1996. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nature Medicine 2(8): 893-898. doi:10.1038/nm0896-893.
13. Ibanga, H.B., R.H. Brookes, P.C. Hill, P.K. Owiafe, H.A. Fletcher, C. Lienhardt, A.V. Hill, R.A. Adegbola, and H. McShane. 2006. Early clinical trials with a new tuberculosis vaccine, MVA85A, in tuberculosis-endemic countries: Issues in study design. The Lancet Infectious Diseases 6(8): 522-528. doi:10.1016/S1473-3099(06)70552-7.
14. Kamath, A.T., U. Fruth, M.J. Brennan, R. Dobbelaer, P. Hubrechts, M.M. Ho, R.E. Mayner, J. Thole, K.B. Walker, M. Liu, and P.H. Lambert. 2005. New live mycobacterial vaccines: The Geneva consensus on essential steps towards clinical development. Vaccine 23(29): 3753-3761. doi:10.1016/j.vaccine.2005.03.001.
15. McElrath, M.J., S.C. De Rosa, Z. Moodie, S. Dubey, L. Kierstead, H. Janes, O.D. Defawe, D.K. Carter, J. Hural, R. Akondy, S.P. Buchbinder, M.N. Robertson, D.V. Mehrotra, S.G. Self, L. Corey, J.W. Shiver, and D.R. Casimiro. 2008. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: A case-cohort analysis. Lancet 372(9653): 1894-1905. doi:10.1016/S0140-6736(08)61592-5.
16. Minnies, D., T. Hawkridge, W. Hanekom, R. Ehrlich, L. London, and G. Hussey. 2008. Evaluation of the quality of informed consent in a vaccine field trial in a developing country setting. BMC Medical Ethics 9: 15. doi:10.1186/1472-6939-9-15.
17. Morrison, J., M. Pai, and P.C. Hopewell. 2008. Tuberculosis and latent tuberculosis infection in close contacts of people with pulmonary tuberculosis in low-income and middle-income countries: A systematic review and meta-analysis. The Lancet Infectious Diseases 8(6): 359-368. doi:10.1016/S1473-3099(08)70071-9.
18. National Institute for Health and Clinical Excellence (NICE). 2006. Tuberculosis: Clinical diagnosis and management of tuberculosis, and measures for its prevention and control. http://www.nice.org.uk/nicemedia/pdf/CG033niceguideline.pdf. Accessed 4 April 2009.
19. Orme, I.M. 2005. The use of animal models to guide rational vaccine design. Microbes and Infection 7(5-6): 905-910. doi:10.1016/j.micinf.2005.03.008.
20. Samson, K. 2008. Orphan economics: The downside of supplyside pharmacology. Annals of Neurology 64(3): A13-A16. doi:10.1002/ana.21432.
21. Selgelid, M.J. 2005. Ethics and infectious disease. Bioethics 19(3): 272-289. doi:10.1111/j.1467-8519.2005.00441.x.
22. Selgelid, M.J., P.M. Kelly, and A. Sleigh. 2008a. Ethical challenges in TB control in the era of XDR-TB. The International Journal of Tuberculosis and Lung Disease 12(3): 231-235.
23. Selgelid, M.J., P.M. Kelly, and A. Sleigh. 2008b. In International Public Health Policy and Ethics, ed. M. Boylan. Dordrecht: Springer.
24. Shisana, O., E.J. Hall, R. Maluleke, J. Chauveau, and C. Schwabe. 2004. HIV/AIDS prevalence among South African health workers. South African Medical Journal 94(10): 846-850.
25. Snider Jr., D.E. 2000. Ethical issues in tuberculosis vaccine trials. Clinical Infectious Diseases 30(Suppl 3): S271-S275. doi:10.1086/313872.
26. Soliman, E.Z. 2008. The ethics of non-inferiority trials. Lancet 371(9616): 895. doi:10.1016/S0140-6736(08)60406-7. author reply 896-7.
27. Tascon, R.E., M.J. Colston, S. Ragno, E. Stavropoulos, D. Gregory, and D.B. Lowrie. 1996. Vaccination against tuberculosis by DNA injection. Nature Medicine 2(8): 888-892. doi:10.1038/nm0896-888.
28. U.S. Department of Health, Education and Welfare. (1979). The Belmont report: Ethical principles and guidelines for the protection of human subjects of research. Federal Register, 44(76): 23191-23197. http://ohsr.od.nih.gov/guidelines/belmont.html. Accessed 4 April 2009.
29. Williams, A., G.J. Hatch, S.O. Clark, K.E. Gooch, K.A. Hatch, G.A. Hall, K. Huygen, T.H. Ottenhoff, K.L. Franken, P. Andersen, T.M. Doherty, S.H. Kaufmann, L. Grode, P. Seiler, C. Martin, B. Gicquel, S.T. Cole, P. Brodin, A.S. Pym, W. Dalemans, J. Cohen, Y. Lobet, N. Goonetilleke, H. McShane, A. Hill, T. Parish, D. Smith, N.G. Stoker, D.B. Lowrie, G. Kallenius, S. Svenson, A. Pawlowski, K. Blake, and P.D. Marsh. 2005. Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis. Tuberculosis (Edinburgh, Scotland) 85(1-2): 29-38. doi:10.1016/j.tube.2004.09.009.
30. World Health Organization. 2007. Global tuberculosis control: surveillance, planning, financing. WHO Report. Geneva: World Health Organisation.
31. World Medical Association. 2008. Declaration of Helsinki. http://www.wma.net/e/policy/b3.htm. Accessed 4 April 2009.